-1.png)
Kalman Tiboldi - CTO & Founder at GemOne-TVH - Simplify or Die: Why Complexity Is the Real IT Challenge
Germany Sep 25, 2025 Country Members Physical english
Join us for an evening of thought-provoking discussions, real-world use cases, and insights from digital leaders, tech-pioneers and academics as we explore the dynamics of the human-machine relationship.
Read More-1.png)
Netherlands Sep 25, 2025 Invitation Only Physical dutch
Alleen op uitnodiging. How can organizations proactively ensure business continuity and IT resilience in 2025 amidst increasing disruptions?
Read More
Germany Sep 29, 2025 Country Members Virtual german
Unsere Wissensaustausch-Briefings "AI & Data Knowledge Transfer" zielen darauf ab, CIDOs und Senior Digital Leaders mit praktischen Anwendungen und umsetzbaren Erkenntnissen von Fachexperten zu vermitteln, die den Weg für transformative digitale Reisen ebnen.
Read More
Germany Sep 30, 2025 Country Members Physical german
Von der Theorie in die Praxis: Erst Business, dann Bier.Unstrukturierte Daten sind das verborgene Kapital vieler Unternehmen – und zugleich eine der größten Herausforderungen moderner IT. Gemeinsam mit CIOs, CDOs und CTOs der CIONET-Community sprechen wir zuerst bei WeWork München über Strategien, Technologien und echte Use Cases, um dieses Potenzial zu heben. Danach geht's weiter auf die Wiesn – für den offenen Austausch in bayerischer Atmosphäre.
Read More.png)
UK Sep 30, 2025 Invitation Only Physical english
This exclusive Jefferson dinner, hosted by Mendix and CIONET, brings together a hand-picked group of senior executives and digital leaders from across the UK financial sector.
Read More
Netherlands Sep 30, 2025 Invitation Only Physical dutch
Alleen op uitnodiging. Mastering Digital Sovereignty Control, trust and resilience in an era of geopolitical and regulatory shifts. From the Network to the Data.
Read More
Exscientia Uses Generative AI to Reimagine Drug Discovery
Exscientia uses generative artificial intelligence (AI) throughout the design-make-test-learn (DMTL) cycle to discover new therapies for patients quickly and relatively inexpensively.
“Using AWS, we reduce bottlenecks and accelerate the pipeline.”
David Hallett
Interim CEO and Chief Scientific Officer, Exscientia
Exscientia uses generative artificial intelligence (AI) throughout the design-make-test-learn (DMTL) cycle to discover new therapies for patients quickly and relatively inexpensively. Conventional drug discovery methods can take up to 15 years and cost over 2 billion dollars, with an average failure rate of 90–96 percent because scientists hunt for specific drug candidates among 1060 bioavailable small molecules.
Built on Amazon Web Services (AWS), Exscientia’s innovative DMTL solution incorporates in silico design—using generative AI algorithms to design compounds in the cloud—and automated robots that make drug candidates in a lab. “We use generative AI to solve for efficiency and effectiveness,” says David Hallett, Exscientia’s interim CEO and chief scientific officer. “By predicting the molecular features of a safe and effective drug in silico, we minimize the number of costly experiments. Our platform, built in collaboration with the AWS team, is optimized for speed. We can repeat many DMTL learning loops, improving our drug candidates with every iteration.”
Working backward from patient needs, Exscientia defines precise target product profiles (TPPs) that specify the complex combination of properties required by a well-tolerated and effective medicine. AI engineers design algorithms that generate panels of potential drug candidates to meet the TPPs. Active learning algorithms help expert designers to select a short list of drug candidates to synthesize in the lab, because they either move the TPPs forward or refine the models for future DMTL cycles.
Exscientia’s algorithms are trained on publicly available pharmacology data and proprietary in-house data generated from patient tissue samples, genomics, single-cell transcriptomics, and medical literature. By encoding data throughout the process and analyzing experimental results and previous design cycles, Exscientia can optimize upcoming design cycles and promote compound designs that are physically synthesizable. Using this synthesis-aware, iterative approach built on AWS, Exscientia makes 10 times fewer compounds than the industry average. “The idea is to iron out chemical liabilities to make safer and more effective drug candidates before we ever test them in patients,” says Hallett.
Exscientia has accelerated drug design by up to 70 percent while decreasing capital cost by 80 percent, compared with industry benchmarks. Using generative AI with other tools, Exscientia not only developed better drug candidates faster but also identified the right drug combinations to trial with patients in the clinic.
Exscientia has incorporated cutting-edge chemistry synthesis and biology assay lab equipment with automation robots to avoid manual handling of lab equipment. Thus, its lab—orchestrated by AWS microservices—can operate 24/7 with minimal human supervision, “When our designs are ready, we can push a button, and within a few days, the robots are making the drug,” says Hallett. Maintaining extremely high levels of security and comprehensive disaster recovery, Exscientia will use this automated robotic capability to reduce the make and test timelines resulting from traditional offshore research contracts used across the industry.
As the company closes the loop with its robotic automation lab, it expects further productivity improvements. Data generated in the lab improves algorithmic predictions and speeds up DMTL cycles.
Six molecules that Exscientia designed using AI have entered clinical trials. “Using AWS, we reduce bottlenecks and accelerate the pipeline,” says Hallett. “By switching on this highly integrated and automated DMTL loop, we can make drug candidates faster and more cost-effective.”
Kalman Tiboldi - CTO & Founder at GemOne-TVH - Simplify or Die: Why Complexity Is the Real IT Challenge
.png)
Isabelle Droll - CIO for Airline, Corporate, Hotels & Resorts and Sustainability at TUI - Data, Diversity, and Destinations
.png)
Sharon Prior - CIO in transition - How Great Tech Leadership Begins with Business Thinking
-1.jpg)
José Antonio López, Group CIO at TOUS - Jewels, Data & AI: Inside the Digital Transformation of TOUS
.png)
Tom Tanghe - General Manager ITC EMEA at Daikin Europe - Reinventing the CIO Role
.jpg)
CIOFEST 2025 - From Order Taker to Proactive Disruptor
As AI transitions from a specialised tool to an all-pervasive force, understanding its profound implications for our human lives is no longer merely academic but an urgent imperative for social well-being and strategic preparedness.
Geopolitical tensions have dominated the headlines for over two years now. In this context, the cyber threat landscape is also evolving rapidly. The protection and security of critical infrastructure – both physical and digital – is becoming increasingly important.
.png?width=600&height=600&name=Anna%20Kopp%20(1).png)
